



Published in final edited form as:

*J Immunol.* 2012 June 15; 188(12): 6347–6356. doi:10.4049/jimmunol.1103781.

## RGS16 attenuates pulmonary T helper type 2/T helper type 17 inflammatory responses

Sucharita P. Shankar<sup>1</sup>, Mark S. Wilson<sup>2</sup>, Jeffrey A. DiVietro<sup>1</sup>, Margaret M. Mentink-Kane<sup>2</sup>, Zhihui Xie<sup>1</sup>, Thomas A. Wynn<sup>2</sup>, and Kirk M. Druey<sup>1,#</sup>

<sup>1</sup>Molecular Signal Transduction Section, Laboratory of Allergic Diseases, National Institutes of Health, Bethesda, MD 20892.

<sup>2</sup>Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.

### Abstract

The Regulators of G protein signaling (RGS) protein superfamily negatively controls G-protein-coupled receptor (GPCR) signal transduction pathways. RGS16 is enriched in activated/effector T lymphocytes. Here, we show that RGS16 constrains pulmonary inflammation by regulating chemokine-induced T-cell trafficking in response to challenge with *Schistosoma mansoni*. Naïve *Rgs16*<sup>-/-</sup> mice were “primed” for inflammation by accumulation of CCR10<sup>+</sup> T cells in the lung. Upon pathogen exposure, these mice developed more robust granulomatous lung fibrosis than wild-type (WT) counterparts. Distinct T<sub>H</sub>2 or putative T<sub>H</sub>17 subsets expressing CCR4 or CCR10 accumulated more rapidly in *Rgs16*<sup>-/-</sup> lungs following challenge and produced pro-inflammatory cytokines IL-13 and IL-17B. CCR4<sup>+</sup> *Rgs16*<sup>-/-</sup> T<sub>H</sub>2 cells migrated excessively to CCL17 and localized aberrantly in challenged lungs. T lymphocytes were partially excluded from lung granulomas in *Rgs16*<sup>-/-</sup> mice, instead forming peribronchial/perivascular aggregates. Thus, RGS16-mediated confinement of T cells to Schistosome granulomas mitigates widespread cytokine-mediated pulmonary inflammation.

### Keywords

Chemokines; G proteins; RGS proteins; *Schistosoma mansoni*; fibrosis; T<sub>H</sub>2; T<sub>H</sub>17; cytokines

## INTRODUCTION

Chemokines dictate coordinated movement of leukocytes through lymphoid organs and sites of inflammation. Naïve and activated leukocyte populations express unique chemokine receptors, and gene-targeting studies have implicated specific chemokines and receptors in leukocyte activation, differentiation, and lymphoid organ development (1). Schistosomiasis, induced by infection with the helminth *S. mansoni* (among other species) represents a global disease burden due to resultant hepatic fibrosis and portal hypertension (2). *S. mansoni* cercariae breach host skin and develop into adult male-female worm pairs that generate hundreds of eggs per day (3, 4). Eggs then enter circulation or embolize in host tissues such as liver, intestine, and lung, where a granulomatous reaction and fibrosis develops in an effort to sequester the foreign eggs antigens (Ag) (3). In published mouse models of Schistosomiasis, the pulmonary granulomatous response is initiated by CD4<sup>+</sup> T<sub>H</sub>2 cells and

<sup>#</sup>To whom correspondence should be addressed at: Laboratory of Allergic Diseases, NIAID/NIH, 10 Center Drive Room 11N242, Bethesda, MD 20892, USA. Ph: 301-435-8875; kdruey@niaid.nih.gov.

their secreted cytokines, particularly IL-13 (5). Although chemokine factors mediating T<sub>H</sub>2 recruitment to lungs acutely challenged with *S. mansoni* eggs have been suggested (e.g. CCL17/CCL22 and CCR4/8), signaling pathways involved in pulmonary inflammation have not been fully defined (6).

Chemokine receptors are G-protein-coupled receptors (GPCRs) linked to G<sub>αi</sub> and possibly G<sub>αq</sub> to induce chemotaxis (7). The primary signal transducer of GPCRs, the heterotrimeric G protein complex of  $\alpha$ ,  $\beta$  and  $\gamma$  subunits, induces pathway activation through GDP-GTP exchange on G $\alpha$  and stimulation of numerous effectors including kinases, phospholipases, and ion channels (8, 9). The intrinsic GTPase activity of the  $\alpha$  subunit, which promotes G $\alpha$  re-association with  $\beta\gamma$  to form an inactive heterotrimer, terminates ligand-induced signaling. The RGS superfamily, which has more than 30 members in mammalian cells, negatively regulates G protein activity (10). All RGS proteins contain a characteristic 120 amino acid “RGS box”, which facilitates binding to G $\alpha$  subunits and GTPase accelerating (GAP) activity (11). RGS GAP activity hastens GPCR pathway inactivation by catalyzing the GTPase reaction. Although molecular determinants of RGS activity have been elucidated over the past decade, most physiological functions of RGS proteins in mammals remain unknown. G $\alpha$ i inactivation by pertussis toxin disrupts physiological hematopoietic cell trafficking including thymic emigration, transendothelial leukocyte migration into lymph nodes, and Ag-induced recruitment of cells to inflamed tissue (7). Because RGS proteins are physiologically relevant inhibitors of G $\alpha$ i, they are poised to regulate chemokine-mediated responses *in vivo* (7).

*RGS16* was initially discovered as an IL-2-dependent activation gene in human T lymphocytes (12). RGS16 may control T<sub>H</sub>2 lymphocyte migration *in vivo* since it is upregulated in activated human T<sub>H</sub>1 and T<sub>H</sub>2 cells relative to naïve T cells, and RGS16 overexpression inhibits T<sub>H</sub> lymphocyte chemotaxis *in vitro* (13). To explore intracellular regulation of chemokine pathways in pulmonary inflammation, we generated *Rgs16*<sup>-/-</sup> mice and studied their response to sensitization with *S. mansoni* egg antigen followed by an intravenous bolus of live *S. mansoni* eggs (14). These studies revealed that RGS16 inhibits T<sub>H</sub>2 chemotaxis to chemokines including CCL17, which constrains T cell localization to Schistosome egg granulomas, thereby reducing the tissue damaging effects of T<sub>H</sub>2-induced pulmonary inflammation by confining cytokines to specific regions(s) of the lung.

## MATERIALS AND METHODS

### Generation of *Rgs16*<sup>-/-</sup> mice

C57/Bl6 WT mice were purchased from Jackson laboratories. *Rgs16*<sup>-/-</sup> mice were generated directly onto a C57/Bl6 background as outlined in Figure 1. All mice were housed in pathogen-free conditions and research performed in accordance with protocols (LAD3e and LPD16e) approved by the National Institutes of Health Institutional Animal Care and Use Committee. Male or female mice between 6 and 12 weeks of age were used for all experiments.

### *S. mansoni* lung challenge model

Mice were sensitized intraperitoneally with 5000 *S. mansoni* eggs that were derived previously from sterile, lipopolysaccharide (LPS)-free Balb/c mice harboring a liver infection (3). 14 days later, mice were challenged intravenously with 5000 live eggs of a Puerto Rican strain of *S. mansoni* (NMRI) as described elsewhere (3). The challenged mice were euthanized at four or seven days post i.v. injection by CO<sub>2</sub> inhalation. Lungs, spleens, and mediastinal lymph nodes (MLNs) were harvested from both groups of challenged mice for analysis.

## Histopathology and immunohistochemistry

Organs were fixed in 10% neutral buffered formalin (EMD Chemicals) and embedded in paraffin. Tissue sections (5  $\mu\text{m}$ ) were evaluated for granuloma volume and diameter by H & E staining, and lung fibrosis was scored based on Picrosirius red stain for collagen using published scoring methods (15). Giemsa stains were utilized to quantify eosinophil numbers. The individual who scored all histological features was blinded to the experimental design. Lungs harvested at 7 days post intravenous challenge were stained for the following markers: anti-CD3 (1:100) (Dako) or anti-CCR10 (1:500) (Abcam). A polyclonal anti-RGS16 antibody (Dru-4) was generated by immunizing rabbits with an N-terminal RGS16 peptide (MCRTLATFPNTC-amide) and collection of serum. The antibody was affinity purified using a peptide-conjugated resin (Spring Valley Laboratories). Slides were deparaffinized and washed twice in distilled water for 5 mins at room temperature (RT). After pre-treatment for antigen retrieval (20-40 mins, 75-90°C), the slides were washed again, and endogenous peroxidase activity was inhibited with  $\text{H}_2\text{O}_2$  for 10 min at RT. Non-specific binding was blocked using 5% bovine serum albumin (BSA) in (Sigma Aldrich) in PBS for 20 min at RT. Sections were incubated with primary antibody or matched isotype controls (1:500) overnight at RT, washed and incubated with the biotinylated secondary antibody (1:500, 30 mins, RT) and finally incubated with streptavidin-horseradish peroxidase (HRP) (1:400, 30 mins, RT) (Alpha Diagnostics Ltd.). Signal was detected with 3,3'-diaminobenzidine (DAB) (1-20 mins, RT). Sections were counterstained in Carazzi hematoxylin (Histoserv, Inc.) for 2 min. at RT followed by dehydration in graded alcohols (75%, 95%, 100%) for 1 min each at RT and xylene (Sigma). Images were obtained with a Leica DMI 4000B microscope and quantified using Image Pro Plus software (Media Cybernetics).

## Real-time PCR and gene expression arrays

Total RNA was isolated using the RNeasy mini kit (Qiagen), followed by DNase I treatment (Invitrogen). cDNA was synthesized from 0.25-1  $\mu\text{g}$  RNA using the Superscript III First-Strand Synthesis kit (Invitrogen). Real-time reverse transcriptase-quantitative PCR (RT-QPCR) was performed using the TaqMan™ strategy (Applied Biosystems). No RT controls were included to verify DNase digestion. Gene expression [*Rgs16* (NM\_011267.3), *Socs2* (NM\_007706.3), *Ccr10* (NM\_007721.4), *Ccl28* (NM\_020279.3), *Il13* (NM\_016971.2), *Il17b* (NM\_019508.1) or the internal reference control  $\beta$ -actin (NM\_007393.3)] was measured by multiplex PCR using probes labeled with 6-carboxy-fluorescein (FAM). The simultaneous measurement of target gene-FAM and  $\beta$ -actin-FAM allowed for normalization of the amount of cDNA added per sample. Duplicate PCR reactions were performed using the TaqMan Universal PCR Master Mix and the ABI 7500 Standard™ or Step One Plus™ sequence detection systems (Applied Biosystems) according to the following thermal cycle routine: 95°C for 10 mins followed by 40 cycles of 95°C for 1 min and 60°C for 20 mins. A comparative threshold cycle ( $C_T$ ) method was used to determine gene expression relative to the no-sample control (calibrator). Steady-state mRNA levels were expressed as an  $n$ -fold difference relative to the calibrator. For each sample, the *RGS16*  $C_T$  value was normalized with the formula:  $\Delta C_T = C_{T \text{ RGS16}} - C_{T \beta\text{-ACTIN}}$ . To determine relative expression levels, the following formula was used:  $\Delta\Delta C_T = \Delta C_{T \text{ sample}} - \Delta C_{T \text{ calibrator}}$ . Relative expression is presented as  $2^{-\Delta\Delta C_T}$ . Multiplex qPCR was performed using a mouse chemokines and receptors qPCR array (SA Biosciences) according to manufacturer's instructions.

## Cytokine analysis

Single cell suspensions were prepared from mediastinal LNs harvested 7 days following i.v. challenge;  $0.5 \times 10^6$  cells/well were plated in triplicate wells of 96-well round polystyrene plates (Corning) in RPMI plus 10% fetal bovine serum (Invitrogen). Cell were left untreated or stimulated with Schistosoma egg antigen (SEA) from *S. mansoni* in PBS (10  $\mu\text{g}/\text{mL}$  final

concentration) for 3 days at 37°C. Cell supernatants were collected and cytokine levels were measured with a fluorescence-based Bio-Plex™ Pro mouse cytokine T<sub>H</sub>1/T<sub>H</sub>2 assay (Bio-rad) according to manufacturer's protocols. Cells were fixed by the addition of PBS containing 2% BSA and 4% paraformaldehyde (PFA) (Electron Microscopy Sciences). ELISAs were performed to quantify secretion of mouse cytokines IL-4, IL-13, IFN $\gamma$ , IL-17A, or IL-17B (R&D Systems) in accordance with manufacturer's protocols.

### Flow cytometry and intracellular staining

Organs were harvested 4 or 7 days post challenge and converted to single cell suspensions followed by fixation in PBS containing 2% BSA and 4% PFA. Surface markers were analyzed with the following antibodies: CD3 (17A2), B220 (RA3-6B2), CD11c (N418) (eBioscience), CD4 (RM4-5), CD8 (53-6.7), CCR3 (83103), CXCR4 (2B11) CXCR3 (CXCR3-173), CCR6 (C34-3448) (BD Biosciences), CCR4 (2G12) (Biolegend), or CCR10 (248918) (R&D Systems) and cytokines were detected with anti-IL-5 (TRFK5) (BD Biosciences), anti-IL-13 (ebio13A), anti-interferon  $\gamma$  (IFN- $\gamma$ ) (XMG1.2) (eBioscience), or anti-IL-17B (R&D Systems). For intracellular cytokine staining, cells were activated with phorbol 12-myristate 13-acetate (PMA) (50 ng/ mL) and ionomycin (0.5  $\mu$ M) (Sigma) for 6 h at 37°C in the presence of brefeldin A (BD Biosciences). Cells were permeabilized with PBS/0.1% saponin (Sigma) and blocked with 5% PBS/milk (Santa Cruz Biotechnology) (15 mins, 4°C) and Fc block (BD Biosciences). Fixed, permeabilized cells were stained in the dark with fluorescently conjugated antibodies (1 h, 4°C) and washed 2X with FACS buffer. Samples were analyzed by flow cytometry using an LSR Fortessa (BD Biosciences), and data analyzed using FlowJo™ (Tree Star Inc).

### In vitro T<sub>H</sub>1, T<sub>H</sub>2 or T<sub>H</sub>17 culture

Single cell suspensions were generated from peripheral LNs from naive mice. Naïve T cells (CD4<sup>+</sup>CD62L<sup>+</sup>) were isolated using the naïve T cell isolation kit II (Miltenyi Biotec).  $3 \times 10^5$  cells per well were plated in 6-well plates pre-coated with anti-CD3 (1  $\mu$ g/ mL) and anti-CD28 (3  $\mu$ g/ mL) containing RPMI medium plus 10% FBS, recombinant mouse IL-4 (10 ng/mL) (Peprotech), anti-mouse IFN $\gamma$  (10  $\mu$ g/ mL) (BD Biosciences) and 50  $\mu$ M 2-mercaptoethanol for 3 days at 37°C. For differentiation into a T<sub>H</sub>1 phenotype, naïve T cells were cultured in media containing IL-2 (10 ng/ mL), IL-12 (10 ng/ mL) (R&D Systems) and anti-IL-4 (10  $\mu$ g/ mL) (eBioscience), referred to as the T<sub>H</sub>1 cocktail. For differentiation into a T<sub>H</sub>17 phenotype, naïve T cells were cultured in media containing IL-23 (5 ng/ mL), IL-21 (100 ng/ mL), IL-6 (10 ng/ mL), hTGF $\beta$  (5 ng/ mL), anti-IL-4 (10  $\mu$ g/ mL), anti-IFN $\gamma$  (10  $\mu$ g/ mL) (R&D Systems) and anti-IL-12 (10  $\mu$ g/ mL) (BD Biosciences), referred to as the T<sub>H</sub>17 cocktail. The differentiated, activated T<sub>H</sub>1 or T<sub>H</sub>2 cells were then expanded in medium containing recombinant mouse IL-2 (10 ng/mL) and IL-7 (5 ng/ mL) (Peprotech) or in IL-2 alone for T<sub>H</sub>17 cells.

### Generation and purification of TAT fusion proteins

The coding region of human *RGS16* was amplified by PCR using pcDNA3.1-RGS16 as a template and subcloned in-frame into pTat-H<sub>6</sub>HA-GFP, which results in an amino-terminally tagged GFP-RGS16 (16). Recombinant TAT fusion proteins were expressed in *Escherichia coli* and purified by nickel-affinity chromatography as described (17). TAT proteins (TAT-GFP-RGS16 or TAT-GFP control) were added directly to T cell cultures for 2 h prior to stimulus addition.

### Chemotaxis assay

Differentiated T<sub>H</sub>2 cells ( $0.5 \times 10^6$  cells/well) were plated in upper wells of 5  $\mu$ m pore polycarbonate membrane Transwell migration chambers containing RPMI plus 0.5% BSA

(Corning). The bottom wells contained chemokines (CXCL12, CCL21, CCL17, CXCL9 or CCL20) (R&D Systems). Control wells, in which upper and lower chambers had equivalent chemokine concentrations, were used to determine chemokinesis. Cells migrated to the lower chamber were counted after 3 h by flow cytometry using a FACSCalibur (BD Biosciences).

### CFSE assay for analysis of cell proliferation

Cells were labeled using the CellTrace™ carboxyfluorescein diacetate succinimidyl ester (CFSE) cell proliferation kit (Invitrogen) plated in 96 well plates left untreated or pre-coated with anti-CD3/anti-CD28. Cells were harvested 4 days later and CFSE dilution profiles evaluated by flow cytometry.

### Statistical analysis

Data sets were compared by student's *t* test for 2 groups or 1 way ANOVA for multiple groups using Graph Pad Prism software. Differences with a *P* value < 0.05 were considered significant.

## RESULTS

### Generation of *Rgs16*<sup>-/-</sup> mice

*Rgs16* was targeted by flanking exons 2 to 4 with *loxP* sites (**Fig. 1A**). We generated knockouts by crossing mice with floxed *Rgs16* allele with Rosa-Cre mice, which have the gene encoding Cre recombinase inserted into the ubiquitous *Rosa26* locus. Correct targeting of the *Rgs16* allele was confirmed by Southern blot (**Fig. 1B**). Homozygous mice were viable and fertile and exhibited no gross phenotypic abnormalities. Architecture of spleen, lungs, and peripheral lymph nodes (LNs) in naïve *Rgs16*<sup>-/-</sup> mice was comparable to WT mice by light microscopy (**Fig. 1C**). Percentages of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, B cells, and dendritic cells (DCs) in, spleen, lungs and LNs were similar in WT and *Rgs16*<sup>-/-</sup> mice (**Table 1**).

### RGS16 inhibits T<sub>H</sub>1 and T<sub>H</sub>2 chemotaxis

To investigate function(s) of RGS16 in T-cell dependent inflammation, we examined its expression pattern in mouse effector T cells and their chemotactic responses. Compared to naïve (CD4<sup>+</sup>CD62L<sup>+</sup>) T cells isolated from peripheral LNs, activated T cells polarized to a T<sub>H</sub>2 phenotype by IL-4 and anti-IFN $\gamma$  antibody expressed 5-fold more *Rgs16* mRNA while those polarized to T<sub>H</sub>1 phenotype by a T<sub>H</sub>1 cocktail or T<sub>H</sub>17 phenotype by a T<sub>H</sub>17 cocktail expressed 2-fold more *Rgs16* mRNA (**Fig. 2A**). We measured chemotaxis of naïve CD4 T cells to gradients of CCL21 and CXCL12 as these chemokines have an important function in homeostatic lymphocyte trafficking in lymphoid organs (18). Consistent with relatively low *Rgs16* expression in naïve CD4 T cells, CXCL12 and CCL21 induced equivalent chemotaxis of naïve splenic CD4 T cells from unchallenged WT and *Rgs16*<sup>-/-</sup> mice (**Fig. 2B**). T<sub>H</sub>2 cells upregulate several “inflammatory” chemokine receptors not typically expressed by naïve cells including CCR4 and CCR8, which mediate trafficking to inflamed tissues containing CCL17 (19). Accordingly, *in vitro* differentiated T<sub>H</sub>2 cells from mice lacking RGS16 migrated much more towards CCL17 gradients than WT counterparts (**Fig. 2C**). At the CCL17 concentration inducing a peak response (50 nM), nearly double the number of RGS16-deficient T<sub>H</sub>2 cells than WT cells migrated to the lower chamber (~ 80% v. 40%).

In contrast to T<sub>H</sub>2 cells, T<sub>H</sub>1 and T<sub>H</sub>17 cells express a distinct set of chemokine receptors including CXCR3 and CCR5 (T<sub>H</sub>1) or CCR6 (T<sub>H</sub>17) (20-22). Similar to the behavior of

RGS16-deficient T<sub>H</sub>2 cells, T<sub>H</sub>1 cells differentiated from *Rgs16*<sup>-/-</sup> mice migrated significantly more towards a gradient of CXCL9 (CXCR3 ligand) than did WT counterparts (Fig. 2C). For unclear reasons, we did not observe significant chemotaxis of murine T<sub>H</sub>17 cells towards CCL20 gradients in transwell assays, independent of genotype (Supplemental Fig. 1). WT and *Rgs16*<sup>-/-</sup> T cells migrated to a similar extent in the presence of equivalent chemokine concentrations in the upper and lower chambers, indicating that the loss of RGS16 affected chemotaxis rather than chemokinesis (Fig. 2D). *Rgs16* expression correlated with chemokine resistance. WT T cells retained in the upper chamber in the presence of a CCL17 gradient for 3 h (“non-migratory”) expressed significantly more *Rgs16* than cells migrating to the lower chamber during that time period (“migratory”) (Fig. 2E). Finally, because WT and *Rgs16*<sup>-/-</sup> T<sub>H</sub> polarized subsets expressed similar levels of surface chemokine receptors including CXCR3 for T<sub>H</sub>1 cells, CXCR4, CCR10, or CCR4 for T<sub>H</sub>2 cells, and CCR6 for T<sub>H</sub>17 cells, these results indicated that RGS16 inhibits chemotaxis downstream of receptors (Supplemental Fig. 1). Consistent with this interpretation, reconstitution of RGS16-deficient T<sub>H</sub>2 cells with TAT-RGS16 reduced CCL17-evoked chemotaxis compared to untreated cells or cells incubated with a control TAT protein (GFP) (Fig. 2F). Collectively, these results suggest that RGS16 directs trafficking of T<sub>H</sub>1 or T<sub>H</sub>2 lymphocytes by curbing their response to chemokine.

### ***Rgs16*<sup>-/-</sup> mice have increased granulomatous lung fibrosis after challenge with *S. mansoni***

To evaluate T<sub>H</sub>2 trafficking *in vivo* in *Rgs16*<sup>-/-</sup> mice and its impact on an acute inflammatory response, we sensitized mice with *S. mansoni* eggs intraperitoneally, followed by intravenous injection of eggs 14 days later (Fig. 3A). Mice were sacrificed 4 and 7 days after the intravenous inoculation, at which time *S. mansoni* eggs embolize in the lungs, resulting in synchronous pulmonary inflammation characterized by granulomas, infiltration of neutrophils, eosinophils, and T<sub>H</sub>2 lymphocytes, and collagen deposition/fibrosis (23). Consistent with a role for RGS16 in the regulation of host responses to *S. mansoni*, *Rgs16* mRNA expression was increased in lungs of sensitized, challenged mice 7 days following intravenous Schistosome challenge (Fig. 3B). We also detected RGS16 in lungs of challenged mice by immunohistochemistry (Fig. 3C). RGS16<sup>+</sup> cells localized predominantly in granulomas surrounding lodged *S. mansoni* eggs. Lungs of *Rgs16*<sup>-/-</sup> mice developed significantly more inflammation and fibrosis than those of WT mice (Fig. 3D). Fibrosis scores (Fig. 3E), granuloma volumes (Fig. 3F), and eosinophil scores (Fig. 3G) were all higher in lungs of knockout mice compared to WT C57/B16 mice. These results indicated that RGS16 constrains acute, granulomatous pulmonary fibrosis induced by *S. mansoni* infection.

### **RGS16 deficiency induces anomalous lymphocyte trafficking *in vivo***

To determine which lymphocyte subsets mediated the atypical fibrotic response of *Rgs16*<sup>-/-</sup> mice lungs to *S. mansoni*, we immunophenotyped pulmonary inflammatory infiltrates by means of flow cytometry. Although we detected no substantial differences in percentages or total numbers of B and T cells in lungs of challenged WT and *Rgs16*<sup>-/-</sup> mice, there was a skewed T<sub>H</sub>2 response in knockout mice as evidenced by increased percentages of IL-13<sup>+</sup> T cells in lungs 4 days following helminth challenge. The ratio of IL-13<sup>+</sup> (T<sub>H</sub>2)/ IFNγ<sup>+</sup> (T<sub>H</sub>1) frequencies was significantly increased in *Rgs16*<sup>-/-</sup> lungs relative to WT (Figs. 4A-B). As T<sub>H</sub> cells from WT and *Rgs16*<sup>-/-</sup> mice exhibited comparable rates of differentiation, proliferation and survival *in vitro* (Supplemental Figure 2 and data not shown), aberrant cell growth and/or death probably did not account for the differences in cellular composition observed.

Splenic CD4 T cells isolated from challenged *Rgs16*<sup>-/-</sup> mice migrated more towards CCL17 gradients than cells from WT mice (Fig. 4C). Thus, irregular trafficking patterns of fibrosis-

inducing IL-13<sup>+</sup> T<sub>H</sub>2 cells might contribute to the enhanced inflammation in *Rgs16*<sup>-/-</sup> mice following helminth challenge. Consistent with this hypothesis, we observed starkly atypical T lymphocyte localization patterns in lungs of RGS16-deficient mice following *S. mansoni* inoculation compared to WT. Whereas T cells were distributed uniformly within fibrotic granulomas surrounding embolized eggs in WT lungs, they were restricted to the periphery of granulomas in lungs of *Rgs16*<sup>-/-</sup> mice (**Fig. 5A**). In addition, we detected dense perivascular/peribronchial T cell aggregates that were largely absent in WT mice (**Figs. 5B-C**). These data suggest that RGS16 attenuates inflammation in Schistosome egg-challenged lungs by retaining T lymphocytes within granulomas.

### RGS16 regulates lymphocyte trafficking in vivo mediated by CCR4 and CCR10

Because T<sub>H</sub>2 cells express CCR4, and RGS16-deficient T cells migrated excessively towards CCL17, we hypothesized that the CCL17/22-CCR4 pathway mediated uncharacteristic migration of a subset of T<sub>H</sub>2 cells (CCR4<sup>+</sup>IL-13<sup>+</sup>) in challenged lungs of *Rgs16*<sup>-/-</sup> mice. Consistent with this hypothesis, we detected CCR4<sup>+</sup>IL-13<sup>+</sup> T cells in the lungs of *Rgs16*<sup>-/-</sup> much earlier than in WT mice (four days after challenge with *S. mansoni*) (**Fig. 6A**). To determine whether other chemokine/receptor pairs contributed to T lymphocyte mis-localization in lungs of helminth-challenged *Rgs16*<sup>-/-</sup> mice, we analyzed differential gene expression by qPCR array (full gene list in **Supplemental Table**). Notably, we found selectively increased expression of *Il17b* and *Ccr10* mRNA in lungs of *Rgs16*<sup>-/-</sup> mice compared to WT. CCR10 is expressed by effector/memory T cells, Langerhans cells and plasma cells, among others (24-26), and its ligands CCL27/28 are produced by epidermal keratinocytes (27) and displayed on the surface of dermal endothelial cells (28). CCR10 expression on skin-homing T<sub>H</sub>2 cells (29) has been implicated in the pathogenesis of T-cell mediated inflammatory skin diseases including atopic dermatitis and contact hypersensitivity (16, 17). We detected CCR10 in lungs of challenged mice by immunohistochemistry, and its staining pattern mirrored T cell localization in WT and *Rgs16*<sup>-/-</sup> mice (predominantly in granulomas or peribronchial/perivascular areas, respectively) (**Fig. 6B**). This result suggests a role for CCR10 in *S. mansoni*-evoked inflammation and in the aberrant trafficking of cytokine-producing T cells we observed in *Rgs16*<sup>-/-</sup> mice.

Although we found decreased or comparable expression of *Ccl17* and CCR10 ligands *Ccl27* and *Ccl28* in lungs of WT and *Rgs16*<sup>-/-</sup> mice (in the presence or absence of *S. mansoni* challenge) (**Fig. 6C, Supplemental Table, and data not shown**), naïve lungs of knockout mice had significantly increased *Ccr10* expression (**Fig. 6D**). We detected CCR10<sup>+</sup> T lymphocytes in naïve lungs of *Rgs16*<sup>-/-</sup> mice but not in WT mice (**Fig. 6E**), suggesting that anomalous migration of RGS16-deficient, CCR10<sup>+</sup> T cells to the lungs accounted for the increased *Ccr10* gene expression. Moreover, lungs from *Rgs16*<sup>-/-</sup> mice, but not from WT mice, contained cytokine-producing CCR4<sup>+</sup> or CCR10<sup>+</sup> T cells (IL-13 or IL-17B) 4-7 days following *S. mansoni* challenge (**Figs. 6F-H**). Collectively, these results indicate that ectopic trafficking of CCR4<sup>+</sup> and CCR10<sup>+</sup> T effector cells to the lungs of *Rgs16*<sup>-/-</sup> mice may exacerbate fibrogenesis in response to pulmonary helminth challenge through enhanced cytokine production.

### Cytokine abnormalities in *S. mansoni*-challenged *Rgs16*<sup>-/-</sup> mice

In addition to increased *Ccr10* expression, array analysis also revealed upregulation of cytokines in helminth-challenged *Rgs16*<sup>-/-</sup> lungs compared to WT—specifically *Il13* and *Il17b*. We confirmed these results by real-time PCR (**Fig. 7A-B**) and investigated the source(s) of cytokines by re-stimulating MLN cells from WT or *Rgs16*<sup>-/-</sup> mice with Schistosome egg antigen (SEA). LN supernatants from *Rgs16*<sup>-/-</sup> mice had significantly more IL-5, IL-10, and IL-13 than WT (**Fig. 7C**). As effector T cells are generally considered

to be the most common sources of these cytokines, we analyzed quantities of LN cytokine-producing CD4 T cells in WT and knockout mice. In contrast to the increased numbers of cytokine<sup>+</sup> T cells present in lungs of *S. mansoni*-challenged *Rgs16*<sup>-/-</sup> mice relative to WT at the earlier time point (4 days post-challenge), frequencies of IL-13<sup>+</sup> or IL-17B<sup>+</sup> T cells and intensity of IL-13 staining were similar in WT and *Rgs16*<sup>-/-</sup> MLNs at the 7 day timepoint (Figs. 7D-E). These results suggested that further characterization of these cell populations is required to determine the source of increased cytokines in MLN supernatants of *Rgs16*<sup>-/-</sup> mice relative to WT following re-exposure to *S. mansoni*.

## DISCUSSION

We have elucidated a function for a modifier of GPCR signaling, RGS16, in a T<sub>H</sub>2-mediated murine pulmonary inflammatory response to helminth challenge—specifically, through regulation of lung T cell trafficking and cytokine production. The loss of RGS16 in mice triggered an enhanced granulomatous reaction in the lung following challenge with *S. mansoni* eggs, resulting in more fibrosis and eosinophil influx, anomalous localization of T cells, and increased cytokine production. This study also highlights an unanticipated function of the CCR10-CCL27/8 chemokine axis and IL-17B in the pathogenesis of *S. mansoni*-associated inflammation.

Several lines of evidence suggest that RGS16 directly controls differentiated T helper/effector T cell migration patterns but does not regulate trafficking of quiescent, naïve T lymphocytes. RGS16 expression is highly upregulated in differentiated mouse and human T<sub>H</sub>1, T<sub>H</sub>2, and T<sub>H</sub>17 cells compared to naïve CD4 T cells [(13) and Fig. 2A]. Chemokines involved prominently in maintenance of lymphoid compartments through induction of lymphocyte extravasation through high endothelial venules of spleen and LNs (CCL21 and CXCL12) induced comparable chemotaxis of naïve WT and RGS16-deficient T cells. In contrast, *Rgs16*<sup>-/-</sup> effector T<sub>H</sub>2 lymphocytes differentiated *in vitro* or cells extracted from *S. mansoni*-challenged lungs had exaggerated chemotaxis towards a T<sub>H</sub>2-associated chemokine (CCL17). The degree of RGS16 expression correlated inversely with the extent of migration, and chemotaxis of *Rgs16*<sup>-/-</sup> T cells was reduced by reconstitution with RGS16. Spleen and LN lymphocyte populations and organ architecture in the absence of immune challenge were unchanged in either RGS16-Tg or *Rgs16*<sup>-/-</sup> mice [(13) and this study] whereas acute inoculation with *S. mansoni* accentuated trafficking of differentiated T<sub>H</sub>2 cells to these sites.

A surprising finding of this study is the anomalous collection of CCR10<sup>+</sup> T<sub>H</sub>2 cells in the lungs of *Rgs16*<sup>-/-</sup> mice. Although the CCR10-CCL27 axis has been previously associated with T<sub>H</sub>2-mediated inflammation in the skin, its role in pulmonary pathology induced by *S. mansoni* challenge was unknown (20). CCL27 is produced in skin epidermal keratinocytes (27) and presented by dermal endothelial cells (28). CCL17 also promotes CCL27 induction by keratinocytes in the presence of TNF $\alpha$  (30). CCL28, another CCR10 ligand, has been implicated in CCR10-mediated leukocyte homing to the respiratory tract in a murine asthma model (31). The presence of similar or reduced amounts of CCL27/28 ligands in lungs of *Rgs16*<sup>-/-</sup> mice compared to WT suggests that aberrant chemotactic responses of RGS16-deficient T cells to these ligands underlies their accumulation in lungs in the absence of immune challenge. However, for unknown reasons we did not observe chemotaxis of T<sub>H</sub>2 cells (WT or knockout) towards these chemokines in Transwell assays *in vitro* despite expression of CCR10.

We also found increased *Il13* expression in challenged lungs of *Rgs16*<sup>-/-</sup> mice relative to WT, consistent with its central contribution to fibrosis induced by helminth infection (32, 33) (34). Although previous work has also defined a role for IL-17A in helminth-associated



inflammation, we observed increased *Il17b* expression in lungs of *S. mansoni* challenged, *Rgs16*<sup>-/-</sup> mice relative to WT but did not detect *Il17a*. These results suggest an unanticipated function of IL-17B in helminth immunity. Among other IL-17 family members, neutralization of IL-17B in a collagen-induced model of murine arthritis suppressed disease progression by reducing cell infiltration and production of pro-inflammatory cytokine such as IL-1  $\beta$ , TNF-  $\alpha$  (35), factors also known to induce *CCL28* in airway epithelial cells (36, 37). Although we detected IL-17B<sup>+</sup> T cells in challenged lungs, it is unclear whether these cells are conventional T<sub>H</sub>17 cells. Indeed, *in vitro* differentiated T<sub>H</sub>17 cells produced IL-17A but not IL-17B (**Supplemental Fig. 3**). Taken together, these findings suggest the presence of a unique pro-inflammatory environment downstream of IL-17B in lungs of *Rgs16*<sup>-/-</sup> mice challenged with *S. mansoni*. The absence of RGS16 may promote T cell chemotaxis to CCL27/28 displayed on the surface of endothelial cells, which could account for the peribronchial/perivascular accumulation of T cells we observed in challenged lungs of *Rgs16*<sup>-/-</sup> mice.

How RGS16 regulates Ag-induced cytokine production requires further study. We detected unique populations of IL-13 or IL-17B cytokine-producing cells expressing CCR10 or CCR4 much earlier in lungs of *Rgs16*<sup>-/-</sup> mice following helminth challenge. Although quantities of cytokine<sup>+</sup> T cells in lungs were equivalent in the two strains by day 7, overall lung cytokine expression was increased in lungs of knockout mice at this time point relative to WT. Additional gene array analysis revealed reduced expression of suppressor of cytokine signaling 2 (*Socs2*) in lungs of naïve *Rgs16*<sup>-/-</sup> mice compared to WT counterparts but not in RGS16-deficient T<sub>H</sub>2 cells differentiated *in vitro* (**Supplemental Fig. 3 and data not shown**). These data suggest that lung T cells in *Rgs16*<sup>-/-</sup> mice are primed for increased T<sub>H</sub>2 cytokine production due to reduced *Socs2* expression (38).

On the other hand, although levels of immunoreactive cytokines in supernatants of Ag-restimulated MLN cells extracted from *Rgs16*<sup>-/-</sup> mice 7 days post *S. mansoni* challenge were significantly higher than those from WT mice, flow cytometric analysis demonstrated equivalent cytokine<sup>+</sup> T cell frequencies and intensity of cytokine staining in these same LN T cell populations. Polarized T<sub>H</sub> cells from WT and *Rgs16*<sup>-/-</sup> mice secreted roughly equivalent cytokine amounts (IFN $\gamma$  for T<sub>H</sub>1; IL-4 or IL-13 for T<sub>H</sub>2; IL-17A for T<sub>H</sub>17) in response to T-cell receptor stimulation with anti-CD3 and anti-CD28 *in vitro* (**Supplemental Fig. 3 and data not shown**). Increased accumulation of specific populations of cytokine-producing T<sub>H</sub> cells in MLNs of *Rgs16*<sup>-/-</sup> mice compared to WT (presumably due to altered trafficking patterns) could also account for the overall increases in secreted cytokines observed. Thus, based on these data alone we cannot yet determine whether Ag-stimulated, RGS16-deficient T lymphocytes generate more cytokine than WT cells on a per cell basis.

Although our work and that of others have shown that RGS proteins inhibit chemokine-mediated lymphocyte chemotaxis and adhesive responses *in vitro* (39, 40), function(s) of RGS proteins in T-cell mediated immunity have not been explored in detail. Surprisingly, *Rgs2*<sup>-/-</sup> mice had reduced footpad swelling following local inoculation with lymphocytic choriomeningitis virus (LCMV) compared to WT, which correlated with impaired proliferation of, and IL-2 production by, RGS2-deficient T cells. Taken together, these results and our studies suggest unique, context-dependent functions of individual RGS proteins in immune cells that may or may not be predictable based on their shared biochemical (GAP) activity. Further exploration of RGS16 in specific T cell populations and in the setting of immune challenges will be needed to fully clarify its function(s) in adaptive immunity. Although we present abundant evidence that anomalous T<sub>H</sub>2 trafficking and increased T-cell derived cytokines contribute to the enhanced pulmonary inflammation in *S. mansoni*-challenged, RGS16-deficient mice relative to WT (**Figs. 4-7**), non-T<sub>H</sub>-dependent

factors may also mediate fibrosis in this setting. Additional models of inflammation and approaches such as adoptive T cell transfer and/or generation of bone marrow chimeras will be needed to determine the relative importance of T-cell intrinsic- and T-cell-independent factors to the immune responses of mice lacking RGS16.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

None


This study was supported by the Intramural Research Program of the NIAID, NIH (Grant AI000746 to K.M.D.)

## REFERENCES

1. Cyster JG. Lymphoid organ development and cell migration. *Immunol Rev.* 2003; 195:5–14. [PubMed: 12969306]
2. Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. *Immunol Rev.* 2004; 201:156–167. [PubMed: 15361239]
3. Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA. Immunopathology of schistosomiasis. *Immunol Cell Biol.* 2007; 85:148–154. [PubMed: 17160074]
4. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. *Nat Rev Immunol.* 2002; 2:499–511. [PubMed: 12094224]
5. Dessein A, Kouriba B, Eboumbou C, Dessein H, Argiro L, Marquet S, Elwali NE, Rodrigues V, Li Y, Doumbo O, Chevillard C. Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. *Immunol Rev.* 2004; 201:180–190. [PubMed: 15361241]
6. Jakubzick C, Wen H, Matsukawa A, Keller M, Kunkel SL, Hogaboam CM. Role of CCR4 ligands, CCL17 and CCL22, during *Schistosoma mansoni* egg-induced pulmonary granuloma formation in mice. *Am J Pathol.* 2004; 165:1211–1221. [PubMed: 15466387]
7. Kehrl JH. Chemoattractant receptor signaling and the control of lymphocyte migration. *Immunol Res.* 2006; 34:211–227. [PubMed: 16891672]
8. Gilman AG. G proteins: transducers of receptor-generated signals. *Annu Rev Biochem.* 1987; 56:615–649.
9. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. *Trends Pharmacol Sci.* 2001; 22:368–376. [PubMed: 11431032]
10. Bansal G, Druey KM, Xie Z. R4 RGS proteins: regulation of G-protein signaling and beyond. *Pharmacol Ther.* 2007; 116:473–495. [PubMed: 18006065]
11. Tesmer JJ, Berman DM, Gilman AG, Sprang SR. Structure of RGS4 bound to AIF4-activated G(i alpha1): stabilization of the transition state for GTP hydrolysis. *Cell.* 1997; 89:251–261. [PubMed: 9108480]
12. Beadling C, Druey KM, Richter G, Kehrl JH, Smith KA. Regulators of G protein signaling exhibit distinct patterns of gene expression and target G protein specificity in human lymphocytes. *J Immunol.* 1999; 162:2677–2682. [PubMed: 10072511]
13. Lippert E, Yowe DL, Gonzalo JA, Justice JP, Webster JM, Fedyk ER, Hodge M, Miller C, Gutierrez-Ramos JC, Borrego F, Keane-Myers A, Druey KM. Role of regulator of G protein signaling 16 in inflammation-induced T lymphocyte migration and activation. *J Immunol.* 2003; 171:1542–1555. [PubMed: 12874248]
14. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. *J Exp Med.* 2000; 191:1069–1076. [PubMed: 10727469]


15. Ramalingam TR, Pesce JT, Sheikh F, Cheever AW, Mentink-Kane MM, Wilson MS, Stevens S, Valenzuela DM, Murphy AJ, Yancopoulos GD, Urban JF Jr, Donnelly RP, Wynn TA. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. *Nat Immunol.* 2008; 9:25–33. [PubMed: 18066066]
16. Bansal G, Xie Z, Rao S, Nocka KH, Druey KM. Suppression of immunoglobulin E-mediated allergic responses by regulator of G protein signaling 13. *Nat Immunol.* 2008; 9:73–80. [PubMed: 18026105]
17. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. *Nat Med.* 1998; 4:1449–1452. [PubMed: 9846587]
18. Stein JV, N.-A. C. Chemokine control of lymphocyte trafficking: a general overview. *Immunology.* 2005; 116:1–12. [PubMed: 16108812]
19. D'Ambrosio D, Iellem A, Bonocchi R, Mazzeo D, Sozzani S, Mantovani A, Sinigaglia A. Cutting Edge: Selective Up-Regulation of Chemokine Receptors CCR4 and CCR8 upon Activation of Polarized Human Type 2 Th Cells. *J Immunol.* 1998; 161:5111–5115. [PubMed: 9820476]
20. Stanford MM, Issekutz TB. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo. *J Leukoc Biol.* 2003; 74:791–799. [PubMed: 12960247]
21. Hirata T, Osuga Y, Takamura M, Kodama A, Hirota Y, Koga K, Yoshino O, Harada M, Takemura Y, Yano T, Taketani Y. Recruitment of CCR6-expressing Th17 cells by CCL 20 secreted from IL-1 beta-, TNF-alpha-, and IL-17A-stimulated endometriotic stromal cells. *Endocrinology.* 2010; 151:5468–5476. [PubMed: 20881253]
22. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T, Sakaguchi N, Sakaguchi S. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. *The Journal of experimental medicine.* 2007; 204:2803–2812. [PubMed: 18025126]
23. Takatsu K, Nakajima H. IL-5 and eosinophilia. *Curr. Opin. Immunol.* 2008; 20:288–294. [PubMed: 18511250]
24. Kagami S, Saeki H, Tsunemi Y, Nakamura K, Kuwano Y, Komine M, Nakayama T, Yoshie O, Tamaki K. CCL27-transgenic mice show enhanced contact hypersensitivity to Th2 but not Th1 stimuli. *Eur J Immunol.* 2008; 38:647–657. [PubMed: 18266301]
25. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, Catron D, Muller A, McClanahan TK, Dieu-Nosjean MC, Orozco R, Ruzicka T, Lehmann P, Oldham E, Zlotnik A. Cutting edge: The orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine (CTACK/ALP/ILC). *J Immunol.* 2000; 164:3465–3470. [PubMed: 10725697]
26. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. *J Immunol.* 2003; 170:1136–1140. [PubMed: 12538668]
27. Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J, Orozco R, Copeland NG, Jenkins NA, McEvoy LM, Zlotnik A. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. *Proc. Natl. Acad. Sci. USA.* 1999; 96:14470–14475. [PubMed: 10588729]
28. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bünemann E, Lehto M, Wolff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, Zlotnik A. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. *Nat. Med.* 2002; 8:157–165. [PubMed: 11821900]
29. Bansal G, DiVietro JA, Kuehn HS, Rao S, Nocka KH, Gilfillan AM, Druey KM. RGS13 controls G protein-coupled receptor-evoked responses of human mast cells. *J Immunol.* 2008; 181:7882–7890. [PubMed: 19017978]
30. Vestergaard C, Johansen C, Christensen U, Just H, Hohwy T, Deleuran M. TARC augments TNF-alpha-induced CTACK production in keratinocytes. *Exp Dermatol.* 2004; 13:551–557. [PubMed: 15335355]

31. English K, Brady C, Corcoran P, Cassidy JP, Mahon BP. Inflammation of the respiratory tract is associated with CCL28 and CCR10 expression in a murine model of allergic asthma. *Immunol Lett.* 2006; 103:92–100. [PubMed: 16290206]
32. Chiamonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. *J Clin Invest.* 1999; 104:777–785. [PubMed: 10491413]
33. McDermott JR, Humphreys NE, Forman SP, Donaldson DD, Grecnis RK. Intraepithelial NK cell-derived IL-13 induces intestinal pathology associated with nematode infection. *J Immunol.* 2005; 175:3207–3213. [PubMed: 16116211]
34. Simonian PL, Roark CL, Wehrmann F, Lanham AK, Diaz del Valle F, Born WK, O'Brien RL, Fontenot AP. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. *J Immunol.* 2009; 182:657–665. [PubMed: 19109199]
35. Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K, Yamamoto K. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. *J Immunol.* 2007; 179:7128–7136. [PubMed: 17982105]
36. O'Gorman MT, Jatoi NA, Lane SJ, Mahon BP. IL-1beta and TNF-alpha induce increased expression of CCL28 by airway epithelial cells via an NFkappaB-dependent pathway. *Cell Immunol.* 2005; 238:87–96. [PubMed: 16581045]
37. Scanlon KM, Hawksworth RJ, Lane SJ, Mahon BP. IL-17A Induces CCL28, Supporting the Chemotaxis of IgE-Secreting B Cells. *Int Arch Allergy Immunol.* 2011; 156:51–61. [PubMed: 21447959]
38. Knosp CA, Carroll HP, Elliott J, Saunders SP, Nel HJ, Amu S, Pratt JC, Spence S, Doran E, Cooke N, Jackson R, Swift J, Fitzgerald DC, Heaney LG, Fallon PG, Kissenpfennig A, Johnston JA. SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses. *The Journal of experimental medicine.* 2011; 208:1523–1531. [PubMed: 21646394]
39. Han JI, Huang NN, Kim DU, Kehrl JH. RGS1 and RGS13 mRNA silencing in a human B lymphoma line enhances responsiveness to chemoattractants and impairs desensitization. *J Leukoc Biol.* 2006; 79:1357–1368. [PubMed: 16565322]
40. Garcia-Bernal D, Dios-Esponera A, Sotillo-Mallo E, Garcia-Verdugo R, Arellano-Sanchez N, Teixido J. RGS10 restricts upregulation by chemokines of T cell adhesion mediated by alpha4beta1 and alphaLbeta2 Integrins. *J Immunol.* 2011; 187:1264–1272. [PubMed: 21705617]




### Figure 1. Generation and characterization of *Rgs16*<sup>-/-</sup> mice

(A) A targeting vector was generated by flanking a floxed-Neo<sup>r</sup> cassette (PGKNeo) by two homologous arms of the endogenous *Rgs16* gene. Shown are restriction maps and exons (solid vertical bars) of the endogenous and targeted *Rgs16* loci (blue bars). (B) WT and floxed alleles were identified by Southern blotting of Bgl II-digested genomic DNA with a 5' probe (red), yielding 10.6 kb or 5.5 kb fragments, respectively (middle). Mice homozygous for the floxed allele were crossed with Rosa-Cre strain, resulting in deletion of PGKNeo and exons 2-4, which was identified as an 8.3 kb fragment. (C) Architecture of spleen, lungs, and peripheral lymph nodes (LNs) in naïve WT or *Rgs16*<sup>-/-</sup> mice was evaluated by H & E staining.




**Figure 2. RGS16 inhibits TH2 chemotaxis**

(A) Naïve T cells were isolated from peripheral LNs and differentiated into TH1, TH2, or TH17 cells as outlined in the Methods. Relative *Rgs16* expression was measured by real-time PCR (\*\* $P = 0.005$ , \* $P < 0.01$ , unpaired  $t$ -test). (B) Whole splenocytes or splenic CD4 T cells C57/B16 and *Rgs16*<sup>-/-</sup> mice were exposed to chemokine gradients in transwell plates for 3 h at 37°C, followed by enumeration of migrated cells by flow cytometry. (C) Migration of TH1 or TH2 cells towards CXCL9 or CCL17 gradients, respectively, at the indicated concentrations was measured as in (B) (\* $P = 0.04$ , \*\* $P < 0.003$ , unpaired  $t$ -test). (D) Chemokinesis was measured by incubating cells with equimolar concentrations of CCL17 (50 nM) in the upper and lower chambers of transwell plates followed by enumeration of cells by flow cytometry. (E) *Rgs16* expression in cells migrated to the lower chamber of CCL17-containing transwell plates (“migratory”) was compared to cells retained in the upper chamber (“non-migratory”) by real-time PCR (\* $P = 0.04$ , paired  $t$ -test). (F) TH2 cells from *Rgs16*<sup>-/-</sup> mice were left untreated or pre-incubated with TAT-GFP or TAT-RGS16 (60-500 nM) for 1 h prior to exposure to CCL17 gradients in transwell assays (\*\*\*)  $P < 0.001$ , 1 way ANOVA, TAT-RGS16 compared to untreated or TAT-GFP. All data are mean  $\pm$  S.E.M of 3-4 independent experiments using cells from 1 mouse/group in each.




**Figure 3. Enhanced pulmonary inflammation in *Rgs16*<sup>-/-</sup> challenged with *Schistosoma mansoni*** (A) Experiment layout. (B) *Rgs16* expression in naïve or *S. mansoni*-challenged lungs was measured by real-time PCR (\**P* = 0.04, unpaired *t*-test). (C) RGS16 expression detected by immunohistochemistry using an RGS16 antibody in lungs of WT or knockout mice as indicated. Images are representative of 3-5 mice/group. (D) Picrosirius red staining for collagen in lungs of WT or *Rgs16*<sup>-/-</sup> mice 7 days following inoculation with *S. mansoni* eggs. (E-G) Fibrosis scores (E), granuloma volumes (F), and eosinophil scores (G) were evaluated in WT and *Rgs16*<sup>-/-</sup> lungs 7 days after helminth challenge. Data represent 8 mice/group evaluated in 2 independent experiments (\**P* < 0.04, unpaired *t*-test).




**Figure 4. Aberrant T<sub>H</sub>2 migration in *Rgs16*<sup>-/-</sup> lungs following *S. mansoni* challenge** (A-B) Frequencies of IL-13<sup>+</sup> or IFN $\gamma$ <sup>+</sup> T cells (CD3<sup>+</sup>) (A) or ratio IL-13<sup>+</sup>/IFN $\gamma$ <sup>+</sup> T cell percentages (B) in lungs 4 days following *S. mansoni* challenge were quantified by flow cytometry (\**P* = 0.04, unpaired *t*-test). Numbers in each quadrant represent percentage of total T cells. (C) Chemotaxis of splenic CD4<sup>+</sup> T cells collected from spleens of WT or *Rgs16*<sup>-/-</sup> mice 4 days following helminth challenge (mean  $\pm$  S.E.M. of 4-5 mice/group, \**P* = 0.03, unpaired *t*-test).






**Figure 5. Anomalous lymphocyte localization in helminth-challenged *Rgs16*<sup>-/-</sup> lungs**  
**(A-B)** T cell localization in helminth-challenged lungs evaluated by immunohistochemistry with a CD3 antibody. Images in (A) show parenchymal T cell accumulation in granulomas while those in (B) demonstrate perivascular/peribronchial cell aggregates (arrowheads). Total area containing cellular aggregates around airways and vessels was quantified using Image Pro Plus software (\* $P=0.04$ , unpaired  $t$ -test) as indicated in (C). Images represent 8 mice/group evaluated in 2 independent experiments.



**Figure 6. Lung lymphocyte populations in *Rgs16*<sup>-/-</sup> mice following helminth challenge** (A) CCR4<sup>+</sup> T<sub>H2</sub> cells (IL-13<sup>+</sup>) in lungs of challenged mice were enumerated by flow cytometry. (B) CCR10 expression in helminth-challenged lungs evaluated by immunohistochemical staining with a CCR10 antibody. (C-D) *Ccl28* (C) or *Ccr10* (D) expression in naïve or *S. mansoni*-challenged lungs evaluated by real-time PCR (\**P* = 0.04, unpaired t-test). (E-G) CCR10<sup>+</sup> T cells in naïve lungs (E), or cytokine<sup>+</sup> CCR10<sup>+</sup> (F) or CCR4<sup>+</sup> (G) T cells in helminth-challenged lungs were quantified by means of flow cytometry. (H) Frequencies of IL-17B<sup>+</sup> T cells (CD3<sup>+</sup>) in lungs 7 days following *S. mansoni* challenge were quantified by means of flow cytometry. Numbers represent percentage of total T cells. All data was generated using 3 naïve mice/ group, 3-5 challenged WT mice or 4-5 challenged *Rgs16*<sup>-/-</sup> mice.



**Figure 7. Cytokine abnormalities in *Rgs16*<sup>-/-</sup> mice inoculated with *S. mansoni***  
**(A-B)** Expression of *Il13* (A) or *Il17b* (B) was evaluated in naïve or helminth-challenge lungs by real-time PCR (\**P* = 0.03; \*\**P* = 0.005, unpaired *t*-test). **(C)** Cells were harvested from lung-draining mediastinal LNs 7 days following inoculation with *S. mansoni*. Cells were left untreated or re-stimulated with Schistome egg Ag (SEA) for 3 days followed by measurement of the indicated cytokine levels in supernatants (\**P* = 0.005; \*\*\**P* = 0.0001, unpaired *t*-test). **(D)** Frequencies of IL-13<sup>+</sup> or INF $\gamma$ <sup>+</sup> T cells (CD3<sup>+</sup>) in LNs 7 days following *S. mansoni* challenge were quantified by means of flow cytometry. Numbers in each quadrant represent percentage of total T cells. Graph on the right shows intensity of IL-13 staining (geometric mean fluorescence intensity, MFI) in the CD4 T cell population. **(E)** Frequencies of IL-17B<sup>+</sup> T cells (CD3<sup>+</sup>) in LNs 4 or 7 days following *S. mansoni* challenge were quantified by means of flow cytometry. All data was generated using 3 naïve mice/ group, 3-5 challenged WT mice or 4-5 challenged *Rgs16*<sup>-/-</sup> mice. For (C), data is representative of 7-8 mice/group evaluated in 2 independent experiments.

**Table 1**

Cellular composition of spleens, lymph nodes or lungs of naive WT or *Rgs16*<sup>-/-</sup> mice.

Tissue	Mice	CD3+ (%)	CD3+ CD4+ (%)	CD3+ CD8+ (%)	B220+ (%)	CD11c+ (%)
Spleen	WT*	41.32±15.42	59.13±5.6	5.06±6.33	49.04±5.51	8.24±8.17
	<i>Rgs16</i> <sup>-/-</sup>	48.69±5.47	58.39±1.55	6.31±6.56	47.8±6.59	4.90±4.05
Lymph node	WT	60.27±6.32	55.52±4.84	N.D.	30.53±4.54	N.D.
	<i>Rgs16</i> <sup>-/-</sup>	63.23±4.27	54.06±1.4	N.D.	32.08±4.62	N.D.
Lung	WT	18.14±3.81	24.12±10.99	0.105±0.06	6.99±2.10	6.54±2.18
	<i>Rgs16</i> <sup>-/-</sup>	23.79±10.17	21.06±18.24	N.D.	7.29±5.85	6.92±3.99

B lymphocytes, T lymphocytes, and dendritic cell percentages in lymphoid organs and lung were determined by means of flow cytometry using the indicated markers. Results are mean ± S.E.M. from 6 mice of each genotype. N.D., not done.